Am J Psychiatry 1994; 151:126-129
Copyright © 1994 by American Psychiatric Association
A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease
C Flicker, SH Ferris, D Kalkstein and M Serby
Department of Psychiatry, New York University Medical Center, NY 10016.
In a double-blind trial, 12 patients with probable Alzheimer's disease were
treated for 6 weeks with placebo and 6 weeks with monosialoganglioside
(GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth
factor. GM1 failed to produce significant improvement in patients'
cognitive test performance, suggesting that this is not a viable approach
to the treatment of cognitive deterioration in Alzheimer's disease.
